RE: Re So springy26 Apr 2019 12:08
Joe - the stem cell business is a loss leader unfortunately. Look at the accounts, revenue of c.£60k and costs of over £2m... it is not a cash injector at all. BUT, with the board changes, the new business model, and hopefully some updates on contracts, we should see a stabilising of the stem cell business (or possibly a sale).
I am still confident that the stem cell business can be successful, and it could be a really big market in the future. For now, we just need to ride out the lows, and look forward to more RNS.
And of course, we have a fledgling media company with all the pieces in place, ready to reward... :)